What’s happening with pharmaceutical tariffs in 2024 and why should importers care?
Benjamin explains that tariffs on certain pharmaceuticals have increased due to concerns about pricing disparities between the U.S. and other countries. Customs has warned companies not to undervalue shipments to avoid appearing overpriced. Additionally, existing Section 301 tariffs remain in place, adding up to 55% total duty on some imports.
How is the U.S. cracking down on de minimis imports and postal shipments from China?
The government is aggressively targeting misuse of the de minimis rule (duty-free imports under $800). Chinese sellers who evade tariffs via postal shipments now face a new “postal tariff” of up to 54%, on top of existing tariffs. A $1 handling fee per parcel has also been added to cover inspection costs.
What’s the impact of FDA leadership changes on importer response times?
Benjamin reports significant delays in getting FDA decisions due to internal restructuring. The former Office of Regulatory Affairs (ORA) was converted into the Office of Inspections and Investigations (OII), stripping field compliance officers of their previous discretion. Now, nearly all regulatory decisions are routed through FDA headquarters, increasing wait times.
How has the FDA’s Freedom of Information Act (FOIA) responsiveness changed?
FOIA response times are worse than ever. Many FOIA functions were consolidated, and staff cuts have left importers struggling to obtain records. Ben notes that FDA was already slow with FOIA before the changes, but it’s now markedly worse.
Are similar enforcement delays occurring with Customs and Border Protection?
No. Customs, which falls under Homeland Security, is actually seeing increased resources. CBP continues to operate efficiently, while FDA bottlenecks persist due to underfunding and reorganization.
How does regulatory uncertainty affect importers’ bottom lines?
Importers often hesitate to bring in new shipments if one is held up, but Ben often advises clients to proceed with future shipments, unless FDA is actively testing the product. Delays tied to minor labeling issues or registrations are now more common, even for previously overlooked compliance issues.
What’s changing in FDA enforcement around food dyes and supplement ingredients?
FDA is increasing scrutiny of food additives, including coloring agents like red dyes and chemical ingredients in highly processed foods. There’s growing pressure to align with other countries that have already banned certain dyes, and broader policy changes are expected in the supplement space, particularly regarding peptides.
What is the status of state-level drug importation programs from Canada?
Florida’s program to import drugs from Canada is moving forward, stemming from a rule finalized under the Trump administration. Although the Biden administration supported the idea, implementation stalled, until now. Benjamin expects further developments that may expand this approach to more states.
How can importers stay agile during regulatory volatility?
Benjamin recommends monitoring FDA news, tariff updates, and especially the agency’s budget. The FDA’s ability to enforce or delay policies depends heavily on what gets funded. He also urges companies to consult experts who understand how FDA actually operates, especially given the growing disconnect between policy goals and agency execution.
If you’re facing challenges with importing FDA-regulated products, we’re here to help you navigate the process smoothly. Let us be your guide through the complexities of trade tariffs, FDA compliance, and border issues. Visit us at FDAImports or contact us directly at contact@fdaimports.com for assistance.
This news update is provided for informational and educational purposes only and does not constitute legal advice and is not intended to form an attorney-client relationship. Please contact your regular FDAImports representative for additional information.
